🇺🇸 FDA

Company profile · Sponsor

Sanofi

Sanofi Pharma Bristol-Myers Squibb

E219E9E · EMA pharma EU
Pipeline
24
Drugs
0
Patents
0

Quick answer

Sanofi (E219E9E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

Company facts

Ticker E219E9E
Exchange EMA
Company type pharma
Headquarters EU

Pipeline (24)

Search pipeline →

  1. -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide

    Sanofi

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  2. -, TACROLIMUS , Amlitelimab, PIMECROLIMUS , Placebo, Amlitelimab

    Sanofi

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  3. A randomized, Phase 3, double-blind, 52-week study to evaluate the efficacy and safety of rilzabrutinib (SAR444671) compared to placebo in adult participants with active IgG4-related disease

    Sanofi

    Immune system diseases

    phase 3 other active

    1 trial

  4. AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , -, Matched Placebo to Test, Matched Placebo for Comparator Teriflunomide, Tolebrutinib, -

    Sanofi

    Nervous system diseases

    phase 3 small molecule active

    1 trial

  5. AUBAGIO 14 mg film-coated tablets, Frexalimab, AUBAGIO 14 mg film-coated tablets, AUBAGIO 14 mg film-coated tablets, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, Matched placebo for comparator teriflunomide, AUBAGIO 14 mg film-coated tablets, Matched placebo for test product frexalimab

    Sanofi

    multiple sclerosis

    phase 3 small molecule active

    1 trial

  6. Amlitelimab, Amlitelimab, -, -, -, Amlitelimab

    Sanofi

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  7. Amlitelimab, Placebo, -, TACROLIMUS , PIMECROLIMUS , Amlitelimab

    Sanofi

    Dermatitis atopic

    phase 3 small molecule active

    1 trial

  8. Amlitelimab, Placebo, Amlitelimab, PIMECROLIMUS , -, TACROLIMUS

    Sanofi

    atopic dermatitis

    phase 3 small molecule active

    1 trial

  9. Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection, Cablivi 10 mg powder and solvent for solution for injection

    Sanofi

    Thrombotic Thrombocytopenic Purpura

    phase 3 small molecule active

    1 trial

  10. Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo 15mg tablets, venglustat GZ402671 - SAR402671, Placebo 6mg tablets, Cerezyme 400 Units Powder for concentrate for solution for infusion, Placebo for Cerezyme, Cerezyme 400 Units Powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671

    Sanofi

    Gaucher's disease type III

    phase 3 small molecule active

    1 trial

  11. Dupilumab, Matched placebo for test product

    Sanofi

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  12. Dupilumab, Matched placebo for test product

    Sanofi

    Neurodermatitis

    phase 3 small molecule active

    1 trial

  13. Duvakitug, Matched placebo for test product

    Sanofi

    Immune system diseases

    phase 3 small molecule active

    1 trial

  14. Duvakitug, matched placebo for test product

    Sanofi

    Immune system diseases

    phase 3 small molecule active

    1 trial

  15. FLUTICASONE , Dupilumab, SALBUTAMOL , BUDESONIDE , MONTELUKAST , Matched placebo for test (dupilumab low dose), Matched placebo for test (dupilumab high dose), BECLOMETASONE , Dupilumab, SALMETEROL AND FLUTICASONE

    Sanofi

    Respiratory tract diseases - Wheezing, Asthma

    phase 3 small molecule active

    1 trial

  16. Fabrazyme 35 mg powder for concentrate for solution for infusion, venglustat GZ402671 - SAR402671, Replagal 1 mg/ml concentrate for solution for infusion., Replagal 1 mg/ml concentrate for solution for infusion., Galafold 123 mg hard capsules, Replagal 1 mg/ml concentrate for solution for infusion.

    Sanofi

    Fabry’s disease

    phase 3 small molecule active

    1 trial

  17. Frexalimab

    Sanofi

    Multiple Sclerosis

    phase 3 small molecule active

    1 trial

  18. Imnovid 3 mg hard capsules, Isatuximab, Dexamethason 4 mg JENAPHARM®, JAMP Pomalidomide, JAMP Pomalidomide, Isatuximab, Imnovid 4 mg hard capsules, JAMP Pomalidomide, MONTELUKAST , Pomalidomide Adalvo 4 mg hard capsules, JAMP Pomalidomide, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 2 mg hard capsules, Imnovid 1 mg hard capsules, Pomalidomide Adalvo 3 mg hard capsules, DEXAMETHASONE, Imnovid 1 mg hard capsules, Isatuximab, Imnovid 2 mg hard capsules, Pomalidomide Adalvo 1 mg hard capsules, Dexamethason

    Sanofi

    Cancer - Plasma cell myeloma recurrent

    phase 3 small molecule active

    1 trial

  19. Itepekimab, Matched Placebo for test product

    Sanofi

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  20. Itepekimab, Matched placebo for test product

    Sanofi

    Chronic rhinosinusitis with nasal polyps

    phase 3 small molecule active

    1 trial

  21. Itepekimab, Matched placebo for test product

    Sanofi

    Chronic Obstructive Pulmonary Disease

    phase 3 small molecule active

    1 trial

  22. LORATADINE , FEXOFENADINE , Dupilumab, Matched placebo to test

    Sanofi

    Pruritus

    phase 3 small molecule active

    1 trial

  23. Live Attenuated Respiratory Syncytial Virus (RSV) ∆NS2/∆1313/I1314L vaccine, Matched

    Sanofi

    Virus diseases

    phase 3 small molecule active

    1 trial

  24. Matched placebo for product, Frexalimab

    Sanofi

    Multiple sclerosis

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is Sanofi?

Sanofi (E219E9E) is a pharma company. headquartered in EU. listed on EMA. NovaPharmaNews links 24 pipeline programs, 0 drugs, and 0 patents to this profile..

What pipeline programs does Sanofi sponsor?

We track 24 ClinicalTrials.gov-linked programs for Sanofi, including -, COLESTYRAMINE , AUBAGIO 14 mg film-coated tablets, -, Matched Placebo to Test, Tolebrutinib, Matched Placebo for Comparator Teriflunomide and 23 more. Open each program for phase, modality, NCT IDs, and indication details.

Where does Sanofi company data come from?

Profiles combine SEC EDGAR (CIK/ticker), ClinicalTrials.gov sponsor links, FDA drug records, and USPTO patent metadata. See our data sources page. This profile is for professional reference, not investment advice.